Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.
Ligand Pharmaceuticals (LGND) had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a "buy" rating on the stock.
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]
CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]